The patient study on Zeqmelit® is fully recruited

All 50 patients in AcuCort's phase IV study ZEQ001 for Zeqmelit® have been enrolled.

The phase IV study ZEQ001 on the oral film Zeqmelit®, an innovative oral film for the treatment of severe and acute allergies, commenced at the end of January. Now, 50 patients have been allocated the oral film for use when needed for acute allergic reactions.

"The patient recruitment has exceeded our already high expectations, indicating the significant patient need for our pharmaceutical product," says Jonas Jönmark, CEO of AcuCort. "Furthermore, the study results can be used in an application to be included in the benefit system of TLV, the Dental and Pharmaceutical Benefits Agency."

The study results will be published in scientific journals and strengthen the product's marketing efforts.

The study is ongoing concurrently with the market launch in the Nordic region, where allergy patients are allocated Zeqmelit® for use when needed for acute allergic reactions.

The purpose of the study, an open-label non-randomized low-intervention study, is to gather valuable scientific data on the use of Zeqmelit® from patients previously prescribed oral corticosteroids for self-treatment of acute allergic reactions.

Dr. Bahram Javizian, the lead investigator for the study and an allergist, elaborates on the study's purpose:

"We want to understand patients' experiences with this biofilm, such as: do they feel confident using it? How do they perceive using it? Perhaps most importantly, do patients carry the medication with them?"

For further information:
Jonas Jönmark, CEO AcuCort AB
Tel: [phone]
Email: [e-mail]

About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.

https://news.cision.com/acucort-ab/r/the-patient-study-on-zeqmelit--is-fully-recruited,c3977943

https://mb.cision.com/Public/15601/3977943/80d556d2a0d18aae.pdf

(c) 2024 Cision. All rights reserved., source Press Releases - English